抗菌肽药物的局限性及应对策略  

Limitations and coping strategies Strategy of Antimicrobial Peptide Drugs

作　　者：康玮 王磊[1] 荆宝琴[1] 张金晓[1] 熊思敏[2] 申秀萍[1] KANG Wei;WANG Lei;JING baoqin;ZHANG Jinxiao;XIONG Simin;SHEN Xiuping(TIPR Drug Assessment Co.Ltd,Tianjin Engineering Research Center of drug preclinical assessment technology,Tianjin 300301,China;Anhui Medical University,Hefei 230032,China)

机构地区：[1]天津药物研究院新药评价有限公司,天津市新药非临床评价技术工程中心,天津300301 [2]安徽医科大学药学院,安徽合肥230032

出　　处：《药物评价研究》2018年第10期1911-1915,共5页Drug Evaluation Research

基　　金：国家科技重大新药创制项目(2015ZX09501004);天津市科技计划项目(16PTGCCX00090)

摘　　要：随着多重耐药的病原体数量持续增加,寻找合适的抗生素替代药物的需求日趋迫切。抗菌肽作为微生物自身的防御武器,尽管还存在毒性高、稳定性低和生产成本高等限制其开发成药物的问题需要解决,但由于其具有广泛的抗菌谱、特殊的抗菌机制以及不容易产生耐药性还是受到广泛的关注。近年来,通过计算机辅助药物设计、化学合成等方式来规避劣势,开发抗菌肽药物,有望成为新一类用于临床的新型抗生素,并取代传统的抗生素成为新的抗感染治疗药物。As the number of muti-drug resistant pathogens continues to increase, the need to find suitable replacements is becoming more urgent. Antimicrobial peptides, as a defensive weapon of microorganisms, have received extensive attention by their wide range of antibacterial spectrum, special antibacterial mechanisms, and insusceptible to drug resistance. However,they are still exist many defects, such as high toxicity, low stability, and high production cost, which limits their development into drugs. In recent years, people have used computer-aided drug design and chemical synthesis to avoid disadvantages and develop antimicrobial peptides. This article reviews the self-limiting condition and design methods of antimicrobial peptides.

关 键 词：抗菌肽 耐药性 稳定性 .毒性 生产成本 

分 类 号：R976[医药卫生—药品]